Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Global Market Report 2025
상품코드:1760740
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 CAGR 9.5%로 성장하여 8억 7,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 자가면역질환의 유병률 증가, 의료 전문가들의 인식 개선, 생물학적 제제 및 표적 치료제의 채택 확대, 자가면역질환 치료에서 적응증 외 약물의 사용 증가 등에 기인할 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 단클론항체 치료의 발전, 차세대 염기서열분석(NGS)의 진단 통합, 면역학 연구의 발전, 기술 주도형 신약개발 플랫폼의 활용 등이 있습니다.
헬스케어 지출 증가는 향후 몇 년 동안 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장의 성장을 촉진할 것으로 예상됩니다. 헬스케어 지출에는 개인, 정부 및 조직이 예방, 진단, 치료 및 질병 관리와 같은 헬스케어 서비스에 지출하는 총 자원이 포함됩니다. 새로운 진단 도구와 치료법의 개발, 도입, 지속적인 치료에는 일반적으로 높은 비용이 들기 때문에 의료기술의 발전이 의료비 지출 증가에 기여하고 있습니다. 의료비 지출은 연구 자금을 지원하고, 첨단 진단 도구에 대한 접근을 용이하게 하며, 질병을 관리하고 통제할 수 있는 전문적 치료법의 가용성을 보장함으로써 WAIHA의 치료를 지원하고 있습니다. 예를 들어, 2024년 5월 영국 통계청은 2022년 실질 의료 사회보장비가 2.8% 증가하고 2023년 전체 의료비가 5.6% 증가했다고 보고했습니다. 따라서 의료비 증가는 WAIHA 치료 시장의 성장을 촉진하는 중요한 요인입니다.
단클론항체 치료의 혁신은 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료의 발전을 촉진하고 있으며, 시장의 주요 기업들은 미충족된 임상적 요구를 충족하고 환자 예후를 개선할 수 있는 최첨단 솔루션 개발에 주력하고 있습니다. 단클론항체는 WAIHA에서 적혈구 파괴를 억제하기 위해 특정 면역 세포와 경로를 표적으로 삼도록 설계된 실험실에서 만든 단백질로, WAIHA에서 적혈구 파괴를 억제하는 것을 목표로 합니다. 예를 들어, 2023년 7월 중국에 본사를 둔 바이오 제약사 IASO BIoTechnology는 미국 식품의약국(FDA)이 WAIHA 및 원발성 면역성 혈소판감소증(ITP)을 포함한 자가면역성 혈액질환의 임상 검사 용도로 IASO-782 주사제를 미국에서 승인했다고 발표했습니다. 이 완전 인간형 단클론항체는 CD19를 표적으로 하며, 다른 Fc 기능을 유지하면서 ADCC 활성을 증가시키기 위해 Fc 변이를 도입했습니다. 이 항체는 CD19+B 세포, 혈장 모세포, 자가 반응성 항체를 생산하는 특정 혈장 세포를 특이적으로 제거합니다. IASO-782는 독특한 기전을 통해 ITP, 자가면역성 용혈성 빈혈(AIHA)과 같은 병원성 B세포 및 형질세포에 의해 유발되는 자가면역질환을 치료할 수 있는 가능성을 가지고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장 : 성장률 분석
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장 실적 : 규모와 성장, 2019-2024년
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 전체 시장(TAM)
제6장 시장 세분화
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장 : 치료 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
코르티코스테로이드
단클론항체
정맥내 면역글로불린(IVIG)
수혈
비장적출술
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
경구
정맥내
피하
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장 : 환자 인구통계별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
유아
성인
노인
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장 : 치유 영역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
원발성 자가면역질환
이차성 자가면역질환
유전적 소인
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
온라인 약국
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장, 코르티코스테로이드 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Prednisone
Dexamethasone
Methylprednisolone
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장, 단클론항체 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Rituximab
Sutimlimab
Bortezomib
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장, 정맥내 면역글로불린(IVIG) 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
표준 IVIG
고용량 IVIG
풀 혈장 유래 면역글로불린
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장, 수혈 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
백혈구 제거 적혈구 수혈
긴급 수혈
표현형 적합 적혈구 수혈
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장, 비장적출술 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
복강경 비장적출술
비장적출 후 예방적 치료
개흉 비장적출술
제7장 지역별·국가별 분석
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장 : 경쟁 구도
온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장 : 기업 개요
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Sanofi S.A.
AstraZeneca Plc
Novartis AG
제31장 기타 주요 기업과 혁신적 기업
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Agios Pharmaceuticals Inc.
Incyte corporation
Mallinckrodt Pharmaceuticals
Hutchison Medipharma Limited
BioCryst Pharmaceuticals Inc.
Xencor Inc.
Annexon Inc.
Rigel Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc.
Momenta Pharmaceuticals Inc.
Immunovant Inc.
Zenas BioPharma Inc.
Alexion Pharmaceuticals Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 전략
온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장, 2029년 : 새로운 기회를 제공하는 국가
온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장, 2029년 : 새로운 기회를 제공하는 부문
온난성 자가면역성 용혈성 빈혈(WAIHA) 치료 시장, 2029년 : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Treatment for warm autoimmune hemolytic anemia (WAIHA) centers on addressing the immune system's abnormal behavior, which causes the body to attack and destroy red blood cells at normal body temperatures. The main objective is to minimize or stop this immune-driven destruction, restore healthy red blood cell counts, and alleviate symptoms including fatigue, shortness of breath, and pallor.
The key treatment options for WAIHA include corticosteroids, monoclonal antibodies, intravenous immunoglobulin (IVIG), blood transfusions, and splenectomy. Corticosteroids are anti-inflammatory medications used to suppress the immune response and reduce inflammation. They can be administered orally, intravenously, or subcutaneously, and are suitable for children, adults, and older patients. These drugs are utilized for primary and secondary autoimmune disorders, as well as those related to genetic predisposition, and are available through hospital, retail, and online pharmacies.
The warm autoimmune hemolytic anemia (WAIHA) treatment market research report is one of a series of new reports from The Business Research Company that provides warm autoimmune hemolytic anemia (WAIHA) treatment market statistics, including warm autoimmune hemolytic anemia (WAIHA) treatment industry global market size, regional shares, competitors with a warm autoimmune hemolytic anemia (WAIHA) treatment market share, detailed warm autoimmune hemolytic anemia (WAIHA) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the warm autoimmune hemolytic anemia (WAIHA) treatment industry. This warm autoimmune hemolytic anemia (WAIHA) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The warm autoimmune hemolytic anemia (WAIHA) treatment market size has grown strongly in recent years. It will grow from $0.55 billion in 2024 to $0.60 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historical period can be linked to factors such as increased healthcare spending, a rise in clinical trials targeting rare hematologic conditions, expanding patient support and advocacy networks, and the growing elderly population.
The warm autoimmune hemolytic anemia (WAIHA) treatment market size is expected to see strong growth in the next few years. It will grow to $0.87 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth during the forecast period can be attributed to the rising prevalence of autoimmune disorders, enhanced awareness among healthcare professionals, the growing adoption of biologics and targeted therapies, and the increasing use of off-label drugs in treating autoimmune conditions. Key trends expected during this period include advancements in monoclonal antibody treatments, the integration of next-generation sequencing (NGS) in diagnostics, progress in immunology research, and the use of technology-driven drug discovery platforms.
The growing healthcare expenditure is expected to drive the expansion of the warm autoimmune hemolytic anemia (WAIHA) treatment market in the coming years. Healthcare expenditure encompasses the total resources spent on health services, including prevention, diagnosis, treatment, and disease management, by individuals, governments, and organizations. Advancements in medical technology are contributing to increased healthcare spending, as the development, implementation, and ongoing care of newer diagnostic tools and treatments typically incur higher costs. Healthcare expenditure supports WAIHA treatment by funding research, facilitating access to advanced diagnostic tools, and ensuring the availability of specialized therapies that manage and control the disease. For example, in May 2024, the UK's Office for National Statistics reported that real-term health and social care expenditures grew by 2.8% in 2022, with overall healthcare spending rising by 5.6% in 2023. Thus, the rising healthcare expenditure is a key factor driving the growth of the WAIHA treatment market.
Innovations in monoclonal antibody therapies are driving progress in the treatment of warm autoimmune hemolytic anemia (WAIHA), with key companies in the market focused on developing cutting-edge solutions to meet unmet clinical needs and enhance patient outcomes. Monoclonal antibodies are laboratory-made proteins designed to target specific immune cells or pathways, aiming to reduce the destruction of red blood cells in WAIHA. For example, in July 2023, IASO Biotechnology, a biopharmaceutical company based in China, announced that the U.S. Food and Drug Administration (FDA) had approved IASO-782 Injection for clinical studies in autoimmune hematological conditions in the U.S., including WAIHA and primary immune thrombocytopenia (ITP). This fully human monoclonal antibody targets CD19 and incorporates Fc mutations to boost ADCC activity while preserving other Fc functions. It specifically depletes CD19+ B cells, plasma blasts, and certain plasma cells responsible for producing auto-reactive antibodies. With its unique mechanism, IASO-782 has potential for treating autoimmune disorders driven by pathogenic B and plasma cells, such as ITP and autoimmune hemolytic anemia (AIHA).
In September 2023, Zenas BioPharma Inc., a biotechnology company from the United States, partnered with Bristol Myers Squibb to develop and distribute the obexelimab antibody, a treatment for autoimmune diseases. This collaboration aims to create and bring to market effective new therapies for autoimmune disorders in key Asia-Pacific regions, addressing significant unmet medical needs and enhancing patient outcomes. Bristol Myers Squibb is a US-based pharmaceutical company, known for its expertise in treating warm autoimmune hemolytic anemia (WAIHA).
Major players in the warm autoimmune hemolytic anemia (WAIHA) treatment market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca Plc, Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Agios Pharmaceuticals Inc., Incyte corporation, Mallinckrodt Pharmaceuticals, Hutchison Medipharma Limited, BioCryst Pharmaceuticals Inc., Xencor Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Immunovant Inc., Zenas BioPharma Inc., Alexion Pharmaceuticals Inc., and Mitsubishi Tanabe Pharma Corporation.
North America was the largest region in the warm autoimmune hemolytic anemia (WAIHA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in warm autoimmune hemolytic anemia (WAIHA) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the warm autoimmune hemolytic anemia (WAIHA) Treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The warm autoimmune hemolytic anemia (WAIHA) treatment market consists of revenues earned by entities by providing services such as diagnostic testing services, immune system monitoring, personalized treatment planning and care coordination services. The market value includes the value of related goods sold by the service provider or included within the service offering. The warm autoimmune hemolytic anemia (WAIHA) treatment market also includes sales of diagnostic kits, immunomodulatory agents, hematology analyzers and red blood cell monitoring tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on warm autoimmune hemolytic anemia (waiha) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for warm autoimmune hemolytic anemia (waiha) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The warm autoimmune hemolytic anemia (waiha) treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
4. Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
9. China Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
9.1. China Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
9.2. China Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
10.1. India Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
11.1. Japan Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
11.2. Japan Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
12.1. Australia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
13.1. Indonesia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
14.1. South Korea Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
14.2. South Korea Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
15.1. Western Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
15.2. Western Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
16.1. UK Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.2. Eastern Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
22.1. Russia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
23.1. North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
23.2. North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
24.1. USA Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
24.2. USA Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
26.1. South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview
26.2. South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
27.1. Brazil Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
